Jazz Pharmaceuticals (NASDAQ:JAZZ) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.
Here’s what investors need to know about the announcement.
Earnings
Jazz Pharmaceuticals missed estimated earnings by 1.43%, reporting an EPS of $4.84 versus an estimate of $4.91.
Revenue was up $31.49 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.08 which was followed by a 1.64% increase in the share price the next day.
Here’s a look at Jazz Pharmaceuticals’s past performance:
| Quarter | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|
| EPS Estimate | 4.43 | 4.24 | 0.32 | 4.66 |
| EPS Actual | 4.51 | 3.95 | -0.07 | 5.17 |
| Revenue Estimate | 942.86M | 895.37M | 975.59M | 939.06M |
| Revenue Actual | 957.32M | 892.81M | 972.12M | 940.65M |
To track all earnings releases for Jazz Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
